Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TRANSDERMAL FENTANYL IN THE MANAGEMENT OF CANCER PAIN IN AMBULATORY PATIENTS - AN OPEN-LABEL PILOT-STUDY
Autore:
HAMMACK JE; MAILLIARD JA; LOPRINZI CL; ROSPOND RM; OFALLON JR; WILWERDING MB; REUTER NF; MICHALAK JC; FIDLER P; MISER AW;
Indirizzi:
MAYO CLIN & MAYO FDN,200 1ST ST SW ROCHESTER MN 55905 UNIV NEBRASKA,MED CTR & ASSOCIATES OMAHA NE 68182 ST CLOUD CLIN INTERNAL MED LTD ST CLOUD MN 00000 SIOUXLAND HEMATOL ONCOL ASSOCIATES SIOUX CITY IA 00000
Titolo Testata:
Journal of pain and symptom management
fascicolo: 4, volume: 12, anno: 1996,
pagine: 234 - 240
SICI:
0885-3924(1996)12:4<234:TFITMO>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSTOPERATIVE PAIN; ANALGESIA; EFFICACY; TRIAL;
Keywords:
TRANSDERMAL FENTANYL; CANCER PAIN; OPIOIDS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
19
Recensione:
Indirizzi per estratti:
Citazione:
J.E. Hammack et al., "TRANSDERMAL FENTANYL IN THE MANAGEMENT OF CANCER PAIN IN AMBULATORY PATIENTS - AN OPEN-LABEL PILOT-STUDY", Journal of pain and symptom management, 12(4), 1996, pp. 234-240

Abstract

We performed an open-label Pilot study to define analgesic efficacy, acceptability and toxicity of transdermal fentanyl in an ambulatory population of patients with cancer pain. Our 7-day study included 35 patients, all of whom had failed a trial of an opioid analgesic conventionally used for moderate pain. Patients received either a 25 mu g/hr or50 mu g/hr fentanyl transdermal patch depending on pier opioid dose. Pain was measured daily utilizing visual analogue (VAS) and categorical (CAT) scales. Hours of nighttime sleep, quality of life, toxicities,and use of rescue medication were also assessed. There was a 24%-29% reduction in mean VAS and CAT pain scores as compared with the baseline and a 25% increase in mean hours of nighttime sleep. Fifty-nine percent of those patients responding (46% of all study patients) were satisfied to very satisfied with the analgesia provided by transdermal fentanyl. Six percent of an study patients were not at all satisfied withthe pain relief obtained. Toxicities were similar to those seen with other opioids. No patient developed severe sedation or respiratory depression. The 25-50 mu g/hr patch appears to be a safe starting dosage in ambulatory patients previously receiving opioids conventionally used for moderate pain.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 07:17:33